David B. Roberts Sells 10,815 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

Key Points

• Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock at an average price of $92.39, resulting in a total transaction of nearly $999,198.
• LeMaitre Vascular reported a quarterly EPS of $0.60, exceeding the consensus estimate of $0.57, alongside a year-over-year revenue increase of 15%.
• The company has announced a quarterly dividend of $0.20 per share, payable on September 4th, with a current yield of 0.8%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David B. Roberts sold 10,815 shares of the company's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total transaction of $999,197.85. Following the sale, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded up $0.10 on Friday, hitting $95.91. The company's stock had a trading volume of 270,698 shares, compared to its average volume of 164,133. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The stock's 50 day moving average is $84.56 and its 200-day moving average is $86.44. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a market capitalization of $2.17 billion, a PE ratio of 46.56, a PEG ratio of 2.47 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same period in the prior year, the company posted $0.52 earnings per share. LeMaitre Vascular's revenue was up 15.0% compared to the same quarter last year. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be paid a $0.20 dividend. The ex-dividend date is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular's dividend payout ratio is 38.83%.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust grew its stake in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier's stock worth $25,000 after buying an additional 287 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in LeMaitre Vascular during the first quarter worth about $26,000. NBC Securities Inc. acquired a new stake in LeMaitre Vascular during the first quarter worth about $36,000. Geneos Wealth Management Inc. boosted its stake in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after purchasing an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $47,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Cantor Fitzgerald upped their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of "Hold" and an average target price of $98.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.